About Stealth BioTherapeutics
Stealth BioTherapeutics is a company based in Newton (United States) founded in 2007 was acquired by Morningside in August 2022. Stealth BioTherapeutics has raised $100 million across 2 funding rounds from investors including CMBC Capital, Morningside and Atlantis Investment. The company has 31 employees as of December 31, 2020. Stealth BioTherapeutics offers products and services including Elamipretide. Stealth BioTherapeutics operates in a competitive market with competitors including Moderna, BridgeBio, Spark Therapeutics, Mereo BioPharma and Amicus Therapeutics, among others.
- Headquarter Newton, United States
- Employees 31 as on 31 Dec, 2020
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Stealth Biotherapeutics Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$100 M (USD)
in 2 rounds
-
Latest Funding Round
$20 M (USD), Post-IPO
Apr 13, 2020
-
Investors
CMBC Capital
& 7 more
-
Employee Count
31
as on Dec 31, 2020
-
Acquired by
Morningside
(Aug 01, 2022)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Stealth BioTherapeutics
Stealth BioTherapeutics offers a comprehensive portfolio of products and services, including Elamipretide.
Investigational therapy to restore mitochondrial function in diseases.
People of Stealth BioTherapeutics
Unlock access to complete
Funding Insights of Stealth BioTherapeutics
Stealth BioTherapeutics has successfully raised a total of $100M across 2 strategic funding rounds. The most recent funding activity was a Post-IPO round of $20 million completed in April 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Stealth BioTherapeutics
Stealth BioTherapeutics has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include CMBC Capital, Morningside and Atlantis Investment.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Multiple sectors are invested in by Morningside, a VC fund.
|
Locked | Locked | Locked | |
|
VC firm funding companies in China and the US
|
Locked | Locked | Locked | |
|
Private equity investments are focused on life science companies.
|
Locked | Locked | Locked |
Investor details for Stealth BioTherapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Stealth BioTherapeutics
Investment portfolio details for Stealth BioTherapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Stealth BioTherapeutics
Detailed financials for Stealth BioTherapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Stealth Biotherapeutics Comparisons
Peer comparison for Stealth BioTherapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Stealth BioTherapeutics
Stealth BioTherapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, Spark Therapeutics, Mereo BioPharma and Amicus Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of therapies for rare and orphan diseases
|
|
| Locked | Locked | Locked |
Developer of therapeutics to treat rare genetic diseases
|
Detailed competitors of Stealth BioTherapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Stealth Biotherapeutics
Complete news archive for Stealth BioTherapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Stealth BioTherapeutics
Stealth BioTherapeutics was founded in 2007 and raised its 1st funding round 11 years after it was founded.
Stealth BioTherapeutics is headquartered in Newton, United States. It is registered at Newton, Massachusetts, United States.
Reenie McCarthy is the current CEO of Stealth BioTherapeutics.
Stealth BioTherapeutics is a funded company, having raised a total of $100M across 2 funding rounds to date.
As of Dec 31, 2020, the latest employee count at Stealth BioTherapeutics is 31.
Founded in 2007 and based in Newton, United States, the biotechnology company is engaged in developing peptide therapies for rare mitochondrial diseases and associated dysfunctions. Mitochondrial Carrier Technology is employed to deliver active candidates to mitochondria. The lead product, Elamipretide, functions as a tetrapeptide that stabilizes cardiolipin, thereby supporting electron transfer and inhibiting apoptosis. Applications are targeted at skeletal, ocular, and cardiorenal conditions stemming from mitochondrial impairment.
Stealth BioTherapeutics's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Stealth BioTherapeutics offers Elamipretide.
Stealth BioTherapeutics has 8 investors. Key investors include CMBC Capital, Morningside, Atlantis Investment, BioVeda China Fund, and Kingdon Capital Management.